Disclosed herein are embodiments of compounds that exhibit Crk-like protein inhibition. The compound embodiments can be used to suppress or prevent tumor cell growth and/or to inhibit a Crk-mediated signaling pathway. Methods of making and using the compound embodiments are disclosed herein.

An abstract heading is required. Please delete this heading section if it is not applicable to your application. For more information regarding the headings of the abstract, please see MPEP 608.01(b).

An abstract heading is required. Please delete this heading section if it is not applicable to your application. For more information regarding the headings of the abstract, please see MPEP 608.01(b).

Disclosed are methods of treating a subject having a disease or disorder by administering a monoamine oxidase inhibitor in combination with a serotonin receptor agonist, which in some embodiments is a deuterated serotonin receptor agonist. In some aspects, the disclosure further relates to pharmaceutical compositions and kits comprising a monoamine oxidase inhibitor and a serotonin receptor agonist. In some embodiments, the monoamine oxidase inhibitor is a MAO-A-selective inhibitor such as CX157, and the serotonin receptor agonist is a serotonin 2A receptor agonist such as N,N-dimethyltryptamine (DMT), or deuterated DMT.

Disclosed are methods of treating a subject having a disease or disorder by administering a monoamine oxidase inhibitor in combination with a serotonin receptor agonist, which in some embodiments is a deuterated serotonin receptor agonist. In some aspects, the disclosure further relates to pharmaceutical compositions and kits comprising a monoamine oxidase inhibitor and a serotonin receptor agonist. In some embodiments, the monoamine oxidase inhibitor is a MAO-A-selective inhibitor such as CX157, and the serotonin receptor agonist is a serotonin 2A receptor agonist such as N,N-dimethyltryptamine (DMT), or deuterated DMT.

A method for delivery of an active antibiotic agent to a localized, infected site involves steps of creating an ointment by combining an active antibiotic agent with a tissue penetrating solvent suitable for solubilizing a non-liquid active pharmaceutical ingredient, a tissue penetrating diluent, and a stabilizer for maintaining the ointment, which also functions to as a stabilizer for maintaining chemical stability and resistance to degradation, adjusting viscosity of the ointment by adjustment of amount of the solvent, determining location and extent of the infected site, and applying a predetermined volume of the ointment over skin at the infected region.

The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.

The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.

The present invention is directed to novel chemical compositions of matter, and in particular novel MDMA class of compounds having substituted methylenedioxyphenethylamine and substituted amphetamine, having a metabolically labile thioether group.